Objectives Emotional distress, including depression, is an important issue for cancer patients and their families. Guidelines recommend the use of antidepressant drugs (ADs) for the management of depression in cancer. This study explores the views of oncology professionals about the inclusion of ADs in treatment plans.
Design Semi-structured interview study. Data were analysed using framework analysis.
Setting A specialist cancer centre and six district general hospitals across the Yorkshire Cancer Network.
Participants 18 randomly selected professionals from lung, breast, urology and colorectal cancer teams: oncologists (n=8), surgeons (n=3), clinical nurse specialists (n=2) and ward nurses (n=5).
Results Three main themes emerged relating to professionals' attitudes, knowledge and behaviour. Positive attitudes were primarily expressed by nurses. However, negative views were expressed about the potential for over-reliance on ADs, and their use constituting ‘giving in’. Doctors reported a lack of confidence in the use of and knowledge about ADs with an associated reluctance to prescribe. The general practitioner (GP) was regarded as the most appropriate professional to prescribe ADs.
Conclusions Cancer professionals highlighted a need for training in the appropriate use of ADs. Further, this research suggests that negative attitudes towards antidepressants may be a factor in their exclusion from treatment plans. The GP is seen to have a key prescribing role for AD therapy; however, it is unclear whether the GPs is asked to do this. This research raises questions about the adequacy of ADs in cancer care and to what extent the GP is able to meet this need.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding National Cancer Research Initiative SuPac 0004. GV and KLA are supported by the Cancer Research UK programme grant (C7775/A7424). Role of Study Sponsors: The study sponsors had no role in the study design; the collection, analysis and interpretation of data; the writing of the report; or in the decision to submit the paper for publication.
Competing interests None.
Ethical approval Leeds (East) Research Ethics Committee, 07/H1306/166, 10 April 2008.
Provenance and peer review Not commissioned; externally peer reviewed.